307 related articles for article (PubMed ID: 14750002)
1. Tolerability and effects of two formulations of oral transmucosal fentanyl citrate (OTFC; ACTIQ) in patients with radiation-induced oral mucositis.
Shaiova L; Lapin J; Manco LS; Shasha D; Hu K; Harrison L; Portenoy RK
Support Care Cancer; 2004 Apr; 12(4):268-73. PubMed ID: 14750002
[TBL] [Abstract][Full Text] [Related]
2. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study.
Portenoy RK; Payne R; Coluzzi P; Raschko JW; Lyss A; Busch MA; Frigerio V; Ingham J; Loseth DB; Nordbrock E; Rhiner M
Pain; 1999 Feb; 79(2-3):303-12. PubMed ID: 10068176
[TBL] [Abstract][Full Text] [Related]
3. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR).
Coluzzi PH; Schwartzberg L; Conroy JD; Charapata S; Gay M; Busch MA; Chavez J; Ashley J; Lebo D; McCracken M; Portenoy RK
Pain; 2001 Mar; 91(1-2):123-30. PubMed ID: 11240084
[TBL] [Abstract][Full Text] [Related]
4. Oral transmucosal fentanyl citrate for the treatment of migraine headache pain in outpatients: a case series.
Landy SH
Headache; 2004 Sep; 44(8):762-6. PubMed ID: 15330821
[TBL] [Abstract][Full Text] [Related]
5. Oral transmucosal fentanyl citrate versus placebo for painful dressing changes: a crossover trial.
MacIntyre PA; Margetts L; Larsen D; Barker L
J Wound Care; 2007 Mar; 16(3):118-21. PubMed ID: 17385588
[TBL] [Abstract][Full Text] [Related]
6. The relative potency of oral transmucosal fentanyl citrate compared with intravenous morphine in the treatment of moderate to severe postoperative pain.
Lichtor JL; Sevarino FB; Joshi GP; Busch MA; Nordbrock E; Ginsberg B
Anesth Analg; 1999 Sep; 89(3):732-8. PubMed ID: 10475315
[TBL] [Abstract][Full Text] [Related]
7. Opioids for the management of breakthrough pain in cancer patients.
Zeppetella G; Davies AN
Cochrane Database Syst Rev; 2013 Oct; (10):CD004311. PubMed ID: 24142465
[TBL] [Abstract][Full Text] [Related]
8. A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial.
Mercadante S; Radbruch L; Davies A; Poulain P; Sitte T; Perkins P; Colberg T; Camba MA
Curr Med Res Opin; 2009 Nov; 25(11):2805-15. PubMed ID: 19792837
[TBL] [Abstract][Full Text] [Related]
9. Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients.
Farrar JT; Cleary J; Rauck R; Busch M; Nordbrock E
J Natl Cancer Inst; 1998 Apr; 90(8):611-6. PubMed ID: 9554444
[TBL] [Abstract][Full Text] [Related]
10. Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain.
Christie JM; Simmonds M; Patt R; Coluzzi P; Busch MA; Nordbrock E; Portenoy RK
J Clin Oncol; 1998 Oct; 16(10):3238-45. PubMed ID: 9779697
[TBL] [Abstract][Full Text] [Related]
11. Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers.
Darwish M; Tempero K; Kirby M; Thompson J
Clin Ther; 2006 May; 28(5):715-24. PubMed ID: 16861093
[TBL] [Abstract][Full Text] [Related]
12. Long-term safety of oral transmucosal fentanyl citrate for breakthrough cancer pain.
Payne R; Coluzzi P; Hart L; Simmonds M; Lyss A; Rauck R; Berris R; Busch MA; Nordbrook E; Loseth DB; Portenoy RK
J Pain Symptom Manage; 2001 Jul; 22(1):575-83. PubMed ID: 11516599
[TBL] [Abstract][Full Text] [Related]
13. Fentanyl buccal tablet.
Messina J; Darwish M; Fine PG
Drugs Today (Barc); 2008 Jan; 44(1):41-54. PubMed ID: 18301803
[TBL] [Abstract][Full Text] [Related]
14. Formulation selection and pharmacokinetic comparison of fentanyl buccal soluble film with oral transmucosal fentanyl citrate: a randomized, open-label, single-dose, crossover study.
Vasisht N; Gever LN; Tagarro I; Finn AL
Clin Drug Investig; 2009; 29(10):647-54. PubMed ID: 19715381
[TBL] [Abstract][Full Text] [Related]
15. Various formulations of oral transmucosal fentanyl for breakthrough cancer pain: an indirect mixed treatment comparison meta-analysis.
Jandhyala R; Fullarton J
BMJ Support Palliat Care; 2012 Jun; 2(2):156-62. PubMed ID: 24654058
[TBL] [Abstract][Full Text] [Related]
16. Newer generation fentanyl transmucosal products for breakthrough pain in opioid-tolerant cancer patients.
Elsner F; Zeppetella G; Porta-Sales J; Tagarro I
Clin Drug Investig; 2011; 31(9):605-18. PubMed ID: 21819159
[TBL] [Abstract][Full Text] [Related]
17. Oral transmucosal fentanyl citrate in the management of breakthrough pain in cancer: an open, multicentre, dose-titration and long-term use study.
Hanks GW; Nugent M; Higgs CM; Busch MA;
Palliat Med; 2004 Dec; 18(8):698-704. PubMed ID: 15623166
[TBL] [Abstract][Full Text] [Related]
18. A randomized, placebo-controlled study of a new sublingual formulation of fentanyl citrate (fentanyl ethypharm) for breakthrough pain in opioid-treated patients with cancer.
Novotna S; Valentova K; Fricova J; Richterova E; Harabisova S; Bullier F; Trinquet F;
Clin Ther; 2014 Mar; 36(3):357-67. PubMed ID: 24508417
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of oral transmucosal fentanyl citrate for prehospital pain control on the battlefield.
Wedmore IS; Kotwal RS; McManus JG; Pennardt A; Talbot TS; Fowler M; McGhee L
J Trauma Acute Care Surg; 2012 Dec; 73(6 Suppl 5):S490-5. PubMed ID: 23192075
[TBL] [Abstract][Full Text] [Related]
20. Oral transmucosal fentanyl citrate: overview of pharmacological and clinical characteristics.
Mystakidou K; Katsouda E; Parpa E; Vlahos L; Tsiatas ML
Drug Deliv; 2006; 13(4):269-76. PubMed ID: 16766468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
